InSite Vision Completes Phase 3 Clinical Study of BromSite for the Reduction of Pain and Inflammation After Cataract Surgery

Published: Jan 10, 2013

ALAMEDA, Calif.--(BUSINESS WIRE)--InSite Vision Incorporated (OTCBB: INSV) today announced that the last patient has completed dosing and evaluation in the Phase 3 clinical trial of BromSite™ (ISV-303) for the reduction of pain and inflammation after cataract surgery. BromSite combines a low dose (0.075%) of the non-steroidal anti-inflammatory drug (NSAID) bromfenac with InSite Vision’s DuraSite® drug delivery technology.

Back to news